Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetes

Current Cardiology Reports

Volumn 15, Issue 2, 2013, Pages

  Taub, Pam R ^a   Higginbotham, Erin ^a   Henry, Robert R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Cardiovascular disease; Glycemic control; Macrovascular disease; Microvascular disease; Type 2 diabetes

Indexed keywords

ACARBOSE; ADIPONECTIN; ALEGLITAZAR; C REACTIVE PROTEIN; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LINAGLIPTIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN; METFORMIN; MIGLITOL; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; VOGLIBOSE;

ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; DRUG SAFETY; FUNCTIONAL STATUS; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN TREATMENT; LIPOPROTEIN BLOOD LEVEL; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE;

EID: 84872054917     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0332-4     Document Type: Article

References (83)

1. Diabetes factsheet 312. In: World Health Organization. 2011. http://who.int/mediacentre/factsheets/fs312/en/index.html. Accessed 20 July 2012.
2. National Diabetes Factsheet. In: Center for Disease Control. 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf . Accessed 17 Jul 2012.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil AW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.
5. Hellar SR. A summary of the ADVANCE trial. Diabetes Care. 2009;32:S357-61.
6. Zoungas S, Galan BE, Ninomiya T, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes. Diabetes Care. 2009;32:2068-74.
7. Duckworth W, Abraira C, Mortiz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-39. A comprehensive summary of VADT aims, methods, and results.
8. Gerstein HC, Miller ME, Genuth S, et al. Long-Term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818-28. A comprehensive summary of ACCORD trial aims, methods, and results.
9. Patel A, MacMahon S, Chalmers J. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-72. (Pubitemid 351831357)
10. Adler AI, Levy JC, Matthews DR, et al. Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67). Diabet Med. 2005;22:206-11.
11. Ismail-Beigi F, Craven T, Baneni MA. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomized trial. Lancet. 2010;276:419-30.
12. Checking your blood glucose. In: American Diabetes Association. http://www.diabetes.org/living-with-diabetes/treatment-And-care/ blood-glucose-control/checking-your-blood-glucose.html. Accessed 17 July 2012.
13. Cardiovascular Disease and Diabetes. In: American Heart Association. http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/ Cardiovascular-Disease-Diabetes-UCM-313865-Article.jsp. Accessed 27 Jul 2012.
14. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59. (Pubitemid 351831356)
15. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemic and risks of vascular events and death. N Engl J Med. 2010;363:1410-8.
16. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med. 2009;122(6 Suppl):S37-50.
17. Kendall DM, Bergenstal RM. Comprehensive management of patients with type 2 diabetes: establishing priorities of care. Am J Manag Care. 2001;7(10 Suppl):S327-43. (Pubitemid 32791478)
18. Skyler JS. Diabetic complications. The importance of glucose control. Endocrinol Metab Clin North Am. 1996;25:243-54. (Pubitemid 26195620)
19. DCCTstudy group. The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-86.
20. Stratton IM, Adler AI, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12. (Pubitemid 30609442)
21. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012;59:635-43.
22. UK Prospective Diabetes Study Group. Effects of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:845-65.
23. American Diabetes Association. Implications of the United Kingdom prospective diabetes study. Diabetes Care. 2002;25 (S1):S28-32.
24. ADVANCE Collaborative Group. ADVANCE-Action in Diabetes and Vascular disease: patient recruitment and characteristics of the study population at baseline. Diabet Med. 2005;22:882-8.
25. Adler AI, Neil HA, Manley SE, et al. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdon prospective diabetes study (UKPDS 47). Am Heart J. 1999;138:S353-9. (Pubitemid 29523299)
26. Colaqiuri S, Cull CA, Holman RR, UKPDS group. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61. Diabetes Care. 2002;25:1410-7. (Pubitemid 41071154)
27. The ACCORD study group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99:21i-33i.
28. Riddle MC, Ambrousius WT, Brillon DJ, et al. Epidemiological relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010;33:983-90.
29. Genuth S, Ismail-Beigi F. Clinical implications of the ACCORD trial. J Clin Endocrinol Metab. 2012;97:41-8.
30. Terry T, Raravikar K. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes?: insights from ACCORD, ADVANCE, and VADT. Curr Cardiol Rep. 2012;14:79-88.
31. Abraira C, Duckworth W, McCarren M, et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2 veterans affairs diabetes trial. J Diabetes Complications. 2003;17:314-22. (Pubitemid 37315940)
32. Saremi A, Moritz TE, Anderson RJ. Rates and determinants of coronary and abdominal aortic artery calcium progression in the veterans affairs diabetes trial (VADT). Diabetes Care. 2012;33:1642-7.
33. Reaven PD, Moritz TE, Schwenke DC. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. Diabetes. 2009;58:2642-8.
34. Zoungas S, Patel A, Chalmers J, et al. Sever hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;163:1410-8.
35. Qaseem A, Humphrey LL, Sweet DE, et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012;156:218-31.
36. Powers AC, D'Alessio D. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In: Brunton L, Chabner B, Knollman B, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 12th ed. USA: McGraw-Hill Companies; 2012. p. 1237-74.
37. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized clinical trial. Lancet. 2005;366:1279-89. (Pubitemid 41416583)
38. Henry RR, Lincoff AM, Mudaliar S, et al. Effect of the duel peroxisome profilerator-Activated receptor-Alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II randomized, dose-ranging study. Lancet. 2009;374:126-35.
39. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicenter, randomized, open-label trial. Lancet. 2009;373:2125-35.
40. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-71. (Pubitemid 46919772)
41. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. In: European Medicines Agency. http://www.ema.europa.eu/docs/en-GB/ document-library/Press-re lease/2010/09/WC500096996.pdf. Accessed 1 August 2012.
42. FDA Drug safety website. http://www.fda.gov/Drugs/DrugSafety/ucm255005. htm#Safety-Announcement. Accessed 18 Jul 2012.
43. Leibel B. An analysis of the University Group Diabetes Study Program: data results and conclusions. Can Med Assoc J. 1971;105 (105):292-4.
44. Stephan D, Winkler M, Kuhner P, et al. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K (ATP) channels. Diabetologia. 2006;49:2039-48.
45. Esposito K, Giugliano D, Nappo F, et al. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110:214-9. (Pubitemid 38924590)
46. Holman RR, Haffner SM, McMurray JJ. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1463-76.
47. Hanefeld M, Cagatau M, Petrowitsch, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: metaanalysis. Eur Heart J. 2004;25:10-6. (Pubitemid 38055587)
48. Emoto T, Sawada T, Hashimoto M, et al. Effect of 3-month repeated administration of Miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. Am J Cardiol. 2012;109:42-6.
49. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;23:486-94. (Pubitemid 37430502)
50. Kaiser T, Sawicki PT. Acarbose for prevention of diabetes, hypertension and cardiovascular events. A critical analysis of the STOPNIDDM data. Diabetologia. 2004;47:575-80. (Pubitemid 38491258)
51. Acarbose Cardiovascular evaluation. In NIH Clinical Trials. 2012. NLM identifier: NCT00829660. http://clinicaltrials.gov/ct2/show/NCT00829660. Accessed 19 Jul 2012.
52. Grieve DJ, Cassidy RS, Green BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol. 2009;157:1340-51.
53. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagonlike peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962-5. (Pubitemid 38282847)
54. Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12:694-9. (Pubitemid 44881367)
55. Nystrom T, et al. Effect of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Physiol Endocrinol Metab. 2004;287:E1209-15. (Pubitemid 39491964)
56. Noyan-Ashraf MH, Momen M, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58:975-83.
57. Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagonlike peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacinginduced dilated cardiomyopathy. Circulation. 2004;110:955-61. (Pubitemid 39128621)
58. Bose AK, Mocanu MM, Carr RD, et al. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54:146-51. (Pubitemid 40105106)
59. Hattori Y, Jojima T, Tomizawa A, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia. 2010;53:2256-63.
60. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122:16-7.
61. Sitagliptin cardiovascular outcome study (TECOS). In: NIH Clinical Trials. NLM Identifier: NCT00790205. http://clinical trials.gov/ct2/show/ NCT00790205?term0TECOS&rank01. Accessed 20 July 2012.
62. CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Climepiride in Patients With Type 2 Diabetes. InL NIH Clinical Trials. NLM Identifier: NCT01243424. http://clinicaltrials.gov/ct2/show/NCT01243424? term0carolina+linagliptin&rank01. Accessed 20 July 2012.
63. Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome, (EXAMINE). In: NIH Clinical Trials. NLM Identifier: NCT00968708. http://clinicaltrials. gov/ct2/show/NCT00968708? term0Examine&rank01. Accessed 20 July 2012.
64. Double blind placebo study of vildagliptin in prehypertensives type II diabetics (Prediab). In NIH Clinical Trials. NLM Identifier: NCT01001962. http://clinicaltrials.gov/ct2/show/NCT01001962?term0PREDIAB&rank01. Accessed 20 July 2012.
65. Effects of vildagliptin on left ventricular function in patients with type 1 diabetes and congestive heart failure. In: NIH Clinical Trials. NLM identifier: NCT00894868. http://clinicaltrials.gov/ct2/show/NCT00894868? term0effect+of+vildagliptin+ on+left+ventricular+function&rank01. Accessed 20 July 2012.
66. Woodworth JR, Howey DC, Bowsher RR. Establishment of timeaction profiles for regular and NPH insulin using pharmacodynamic modeling. Diabetes Care. 1994;17:64-9. (Pubitemid 24987655)
67. Anselmino M, Ohrvik J, Malmberg K, et al. Glucose lowering treatment in patients with coronary arter disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J. 2008;29:177-84.
68. Smooke S, Horwich TB, Fonarow GC, et al. Insulin-Treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005;149:168-74. (Pubitemid 40126505)
69. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of Hba (1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375:481-9.
70. Gamble JM, Simpson SH, Eurich DT, et al. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab. 1987;12:47-53.
71. Rensing KL, Reuwer AQ, Arsenault BJ, et al. Reducing cardiovascular disease risk in patients with type 2 diabtes and concomitant macrovascular disease: can insulin be too much of a good thing? Diabetes Obes Metab. 2011;13:1073-87.
72. Gerstein HC, Bosch J, Dagenais GR. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012. doi:10.1056/NEJMoa1203858.
73. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357:1716-30. (Pubitemid 350005153)
74. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736-47.
75. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemic in type 2 diabtes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-96.
76. Kim J, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res. 2008;102:401-14. (Pubitemid 351651099)
77. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-67.
78. Lindsey JB, de Lemos JA, Cipollone F. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis observations from the Dallas Heart Study. Diabetes Care. 2009;32:1218-20.
79. Juraschek SP, Steffes MW, Miller 3rd ER, Selvin E. Alternative markers of hyperglucemia and risk of diabetes. Diabetes Care. 2012. doi:10.2337/dc12-0787. Illustrates the potential use of new biomarkers for diagnosing and treating diabetes.
80. Nishikawa T, Sasahara T, Kiritoshi S, et al. Evaulation of urinary 8-hydroxydeoxyguanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care. 2003;26:1507-12.
81. NICE clinical guideline 87 -Type 2 diabetes. In: Type 2 diabetes. The management type 2 diabetes. National Institute for Health and Clinical Excellence. http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf. Accessed 13 Sep 2012.
82. Simmons RK, Coleman RL, Price HC, et al. Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in estimating cardiovascular disease in the EPICNorfolk cohort. Diabetes Care. 2009;32:708-13.
83. van Dieren S, Peelen ML, Nothlings U, et al. External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes. Diabetologia. 2011;54:264-70.